Results 61 to 70 of about 14,564 (189)
Neovascular age‐related macular degeneration without drusen
Acta Ophthalmologica, Volume 104, Issue 3, Page e300-e311, May 2026.Abstract Purpose To describe the clinical characteristics and 1‐year follow‐up of patients with neovascular AMD (nAMD) without drusen in either eye. Methods This is a multicentre retrospective cohort study in three tertiary referral centres in The Netherlands. We included patients of 55 years or older with nAMD in one or both eyes, without the presence
Marc J. Sirks +9 more
wiley +1 more source
Effect of aflibercept combined with triamcinolone acetonide on aqueous humor growth factor and inflammatory mediators in diabetic macular edema [PDF]
International Journal of OphthalmologyAIM: To investigate the efficacy of aflibercept combined with sub-tenon injection of triamcinolone acetonide (TA) in treating diabetic macular edema (DME) and to examine changes in growth factors and inflammatory mediator levels in aqueous humor after ...
De-Shuang Li +3 more
doaj +1 more source
Twelve‐Month Real‐World Outcomes of Faricimab for Treatment‐Naive Neovascular AMD in Australia
Clinical &Experimental Ophthalmology, Volume 54, Issue 4, Page 500-506, May/June 2026.ABSTRACT Background To provide insights into the effectiveness and safety of faricimab for treatment‐naïve eyes with neovascular age‐related macular degeneration (nAMD). Methods A retrospective cohort study using a prospectively‐designed registry. Treatment‐naïve eyes with nAMD in Australia starting treatment with faricimab between Jan 2023–Sep 2024 ...
Mark Gillies +8 more
wiley +1 more source
Indian Journal of Ophthalmology, 2015 In this study, we reported the clinical results of switching from ranibizumab to aflibercept for the treatment of an insufficient responder with choroidal neovascularization (CNV) secondary to angioid streaks (AS).
Ebru Esen +2 more
doaj +1 more source
Intravitreal ziv-aflibercept for macular edema following retinal vein occlusion
, 2016 Remya Paulose,1 Jay Chhablani,1 Chintan J Dedhia,1 Michael W Stewart,2 Ahmad M Mansour3,4 1Smt. Kanuri Santhamma Centre for Vitreoretinal Diseases, LV Prasad Eye Institute, Hyderabad, India; 2Department of Ophthalmology, Mayo Clinic, Jacksonville, FL ...
Paulose R +4 more
core
Genes to Cells, Volume 31, Issue 3, May 2026.The effects of intraocular administration of neutralizing antibodies against VEGFA, ANG‐2, or bispecific to these two factors on pathological findings were examined in the oxygen‐induced retinopathy (OIR) mouse model. The antibody to VEGFA or ANG‐2 attenuated oxygen‐induced neovascularization and inflammation, and the bispecific antibody more ...
Hirokazu Oohashi +8 more
wiley +1 more source
, 2018 Rafael Campos Polo, Consuelo Rubio Sánchez, Diego Manuel García Guisado, María José Díaz Luque Unit of Retina, Department of Ophthalmology, Hospital Virgen del Puerto, Plasencia, Cáceres, Spain Purpose: To ...
Rubio Sánchez C +3 more
core
Safety profiles of anti-VEGF drugs: bevacizumab, ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture [PDF]
, 2014 PurposeTo compare the safety profiles of antivascular endothelial growth factor (VEGF) drugs ranibizumab, bevacizumab, aflibercept and ziv-aflibercept on retinal pigment epithelium cells in culture.MethodsHuman retinal pigment epithelium cells (ARPE-19 ...
Kuppermann, Baruch D +6 more
core +1 more source
, 2016 Andrii R Korol, Oleg S Zadorozhnyy, Volodymyr O Naumenko, Taras B Kustryn, Nataliya V Pasyechnikova The Filatov Institute of Eye Diseases and Tissue Therapy of the National Academy of Medical Sciences of Ukraine, Odessa, Ukraine Purpose: To determine ...
Pasyechnikova NV +4 more
core